blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3313883

EP3313883 - NOVEL PD-1 IMMUNE MODULATING AGENTS [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  03.11.2023
Database last updated on 19.07.2024
FormerGrant of patent is intended
Status updated on  04.07.2023
FormerExamination is in progress
Status updated on  26.03.2019
FormerRequest for examination was made
Status updated on  30.03.2018
FormerThe international publication has been made
Status updated on  30.12.2016
Most recent event   Tooltip19.07.2024Lapse of the patent in a contracting state
New state(s): EE		published on 21.08.2024 [2024/34]
Applicant(s)For all designated states
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065 / US
For all designated states
Eureka Therapeutics, Inc.
5858 Horton Street, Suite 370
Emeryville, CA 94608 / US
[2023/49]
Former [2018/18]For all designated states
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065 / US
For all designated states
Eureka Therapeutics, Inc.
5858 Horton Street, Suite 370
Emeryville, CA 94608 / US
Inventor(s)01 / BRENTJENS, Renier J.
140 Old Short Hills Road
Short Hills, New Jersey 07078 / US
02 / JACKSON, Hollie Jaine
111 Hambleton St.
Middle Park, VIC 3206 / AU
03 / LIU, Cheng
4 Commodore Drive
D334
Emeryville, California 94608 / US
 [2018/19]
Former [2018/18]01 / BRENTJENS, Renier J.
140 Old Short Hills Road
Short Hills, New Jersey 07078 / US
02 / JACKSON, Hollie Jaine
133 Grand Street Apt. 4
Hoboken, New Jersey 07030 / US
03 / LIU, Cheng
4 Commodore Drive
D334
Emeryville, California 94608 / US
Representative(s)Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
[2023/49]
Former [2018/18]Boynton, Juliette Alice
Schlich
9 St. Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
Application number, filing date16736667.323.06.2016
[2018/18]
WO2016US39015
Priority number, dateUS201562183297P23.06.2015         Original published format: US 201562183297 P
US201562266398P11.12.2015         Original published format: US 201562266398 P
[2018/18]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016210129
Date:29.12.2016
Language:EN
[2016/52]
Type: A1 Application with search report 
No.:EP3313883
Date:02.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 29.12.2016 takes the place of the publication of the European patent application.
[2018/18]
Type: B1 Patent specification 
No.:EP3313883
Date:06.12.2023
Language:EN
[2023/49]
Search report(s)International search report - published on:EP29.12.2016
ClassificationIPC:C07K16/28, A61K39/395, A61K35/17, A61K39/00, A61K38/00, A61K48/00, C07K14/705, C07K14/725, A61P35/00
[2023/30]
CPC:
C07K16/2818 (EP,CN,KR,US); C07K14/00 (KR); A61K35/17 (US);
A61K39/39558 (EP,US); A61K39/4611 (EP,CN,KR); A61K39/4621 (EP,CN,KR);
A61K39/4631 (EP,CN,KR); A61K39/46434 (EP,CN,KR); A61K39/464411 (EP,CN,KR);
A61K39/464412 (EP,CN,KR); A61K47/6849 (US); A61K48/00 (EP,US);
A61P35/00 (EP,CN,US); C07K14/70503 (EP,KR,US); C07K14/7051 (EP,CN,KR,US);
C07K16/2803 (EP,CN,KR,US); C07K16/30 (US); C12N5/0636 (EP,CN,KR);
A61K2035/124 (US); A61K2039/505 (US); A61K2039/507 (EP,CN,KR,US);
A61K2239/31 (EP,CN,KR); A61K2239/38 (EP,CN,KR); A61K2239/48 (EP,CN,KR);
A61K38/00 (EP,KR,US); C07K2317/21 (US); C07K2317/54 (US);
C07K2317/55 (US); C07K2317/56 (CN,US); C07K2317/565 (CN,US);
C07K2317/622 (EP,CN,KR,US); C07K2317/73 (EP,CN,KR,US); C07K2317/75 (US);
C07K2317/76 (EP,CN,KR,US); C07K2319/03 (EP,CN,KR,US); C07K2319/33 (CN);
C07K2319/74 (CN); C12N2510/00 (CN); C12N2740/10043 (EP,US) (-)
C-Set:
A61K39/39558, A61K2300/00 (EP,US)
Former IPC [2018/18]C07K16/28, A61K39/395, A61K35/17, A61K39/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/18]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:NEUARTIGE PD-1-IMMUNMODULIERENDE MITTEL[2018/18]
English:NOVEL PD-1 IMMUNE MODULATING AGENTS[2018/18]
French:NOUVEAUX AGENTS DE MODULATION IMMUNITAIRE PD -1[2018/18]
Entry into regional phase22.01.2018National basic fee paid 
22.01.2018Designation fee(s) paid 
22.01.2018Examination fee paid 
Examination procedure22.01.2018Amendment by applicant (claims and/or description)
22.01.2018Examination requested  [2018/18]
22.01.2018Date on which the examining division has become responsible
29.03.2019Despatch of a communication from the examining division (Time limit: M06)
08.10.2019Reply to a communication from the examining division
20.08.2020Despatch of a communication from the examining division (Time limit: M04)
18.12.2020Reply to a communication from the examining division
25.08.2021Despatch of a communication from the examining division (Time limit: M04)
17.12.2021Reply to a communication from the examining division
05.07.2023Communication of intention to grant the patent
27.10.2023Fee for grant paid
27.10.2023Fee for publishing/printing paid
27.10.2023Receipt of the translation of the claim(s)
Fees paidRenewal fee
11.06.2018Renewal fee patent year 03
13.06.2019Renewal fee patent year 04
31.03.2020Renewal fee patent year 05
14.06.2021Renewal fee patent year 06
31.03.2022Renewal fee patent year 07
31.03.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipEE06.12.2023
ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
[2024/34]
Former [2024/33]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
SM06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/32]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
IS06.04.2024
Former [2024/26]ES06.12.2023
HR06.12.2023
LT06.12.2023
LV06.12.2023
NL06.12.2023
RS06.12.2023
SE06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
Former [2024/24]ES06.12.2023
HR06.12.2023
LT06.12.2023
RS06.12.2023
SE06.12.2023
BG06.03.2024
NO06.03.2024
GR07.03.2024
Former [2024/21]LT06.12.2023
BG06.03.2024
GR07.03.2024
Former [2024/20]GR07.03.2024
Cited inInternational search[Y]WO2014134165  (SLOAN KETTERING INST CANCER [US]) [Y] 37-39* Comments on Fig. 21;; figure 21 *;
 [IY]  - JOHN L B ET AL, "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 20, doi:10.1158/1078-0432.CCR-13-0458, ISSN 1078-0432, (20131015), pages 5636 - 5646, (20130719), XP002737460 [I] 1-16 * see in particular the paragraph Results "PD-1 blockade enhances the proliferative and functional capacity of anti-HER2 T cells in vitro" * [Y] 37-39

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0458
 [I]  - KEICHIRO MIHARA ET AL, "Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma", BRITISH JOURNAL OF HAEMATOLOGY, (20101001), vol. 151, no. 1, doi:10.1111/j.1365-2141.2010.08297.x, ISSN 0007-1048, pages 37 - 46, XP055086001 [I] 17-36,40,41 * see in particular the paragraph "Synergistic cytotoxicity of human peripheral T cells expressing anti-CD19-CAR or anti-CD38-CAR with rituximab treatment in vivo" *

DOI:   http://dx.doi.org/10.1111/j.1365-2141.2010.08297.x
by applicant   - Methods in Enzymology, ACADEMIC PRESS, INC.
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HUSTON ET AL., PROC. NATL. ACAD. SCI., (1988), vol. 85, pages 5879 - 5883
    - YASMINA NA ET AL., "Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors", PROTEIN SCIENCE, (2008), vol. 17, no. 8, pages 1326 - 1335
    - ROBERTS WK ET AL., "Vaccination with CD20 peptides induces a biologically active, specific immune response in mice", BLOOD, (2002), vol. 99, no. 10, pages 3748 - 3755
    - LOUIS C.U., BLOOD, vol. 118, no. 23, pages 6050 - 6056
    - MAUDE S.L. ET AL., N. ENGL. J. MED., (2014), vol. 371, no. 16, pages 1507 - 1517
    - BRENTJENS R.J. ET AL., BLOOD, (2011), vol. 118, no. 18, pages 4817 - 4828
    - KOCHENDERFER J.N. ET AL., BLOOD, (2010), vol. 116, no. 20, pages 4099 - 4102
    - BRENTJENS ET AL., "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory ?-cell leukemias", BLOOD, (201111), vol. 118, no. 18, pages 4817 - 4828
    - BRENTJENS, R. J.; M. L. DAVILA ET AL., "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia", SCI TRANSL MED, (2013), vol. 5, no. 177, page 177RA138
    - BRENTJENS, R. J.; J. B. LATOUCHE ET AL., "Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15", NAT MED, (2003), vol. 9, no. 3, pages 279 - 286
    - BRENTJENS, R. J.; E. SANTOS ET AL., "Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts", CLIN CANCER RES, (2007), vol. 13, pages 5426 - 5435
    - DAVILA, M. L.; I. RIVIERE ET AL., "Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia", SCI TRANSL MED, (2014), vol. 6, no. 224, page 224RA225
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.